Takeda is heading to the FDA with positive PhIII results for HyQvia in rare autoimmune disease
Eight years into its marketing odyssey, Takeda says it’s ready to pitch HyQvia for a new indication.
Late last week Takeda — which wound up with the drug from its Shire buyout — reported successful results of its Phase III clinical trial for its drug as a maintenance therapy for a rare autoimmune disorder, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). And its research team believes HyQvia is ready to win approval for this label add.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.